Maine — Antipsychotic medication usage in Maine’s nursing homes is defying a national downward trend, according to recent reports. While the use of these drugs has decreased across the United States since 2011, Maine’s figures have recently leveled out or begun to rise.
This pattern emerges despite ongoing federal efforts to limit the use of antipsychotic medications, particularly for dementia-related behaviors. These medications carry FDA black-box warnings due to risks like increased mortality for elderly dementia patients. Since 2012, federal initiatives have targeted the reduction of inappropriate prescribing in nursing homes.
Shifting Trends in Maine
The Maine Monitor indicates that while Maine initially saw a decrease in antipsychotic use following nationwide efforts, rates within the state have since started to climb. This shift appears to diverge from the longer-term national trend that continues downward.
Reports highlight the inadequacies in detail concerning specific facilities or the percentage of residents affected in Maine, leaving room for concerns over enforcement and oversight.
Federal and Regulatory Landscape
Regulated by the Centers for Medicare & Medicaid Services (CMS) through the Minimum Data Set assessments, the use of psychotropic medications remains under scrutiny. While Maine-specific regulations or initiatives in this area haven’t been specified, the broader oversight might need bolstering to address local variations.
Broader Implications
Maine’s trends might reflect specific state-level issues such as resource shortages or challenges in adopting non-drug interventions, as discussed in broader industry analyses. These factors could contribute to the inconsistency with national declines.
Experts continue to call for heightened attention to prescribing practices, especially as the nationwide focus on other psychotropic medications hasn’t fully addressed the complexities of antipsychotic use.
